Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

GEHC

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

GEHC

AI Research Report

Powered by Claude

Ready to analyze GEHC

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 14d (Apr 29)

Analyst Consensus

Buy
Based on 28 analysts
Period: 2026-04-01
19 Buy (68%)8 Hold (29%)1 Sell (4%)
Rating Distribution
Strong Buy
8
Buy
11
Hold
8
Sell
1
Strong Sell
0
Trend
2026-04
19/8/1
2026-03
19/8/1
2026-02
19/8/1
2026-01
19/9/0
GE Healthcare Technologies Inc

GE Healthcare Technologies Inc

Health Care·NASDAQ NMS - GLOBAL MARKET·US·IPO 2022-12-15
NASDAQ NMS - GLOBAL MARKETMarket closed
GE Healthcare Technologies Inc
Health Care
$74.71
$0.88 (+1.19%)
Open
$73.96
Prev close
$73.83
Day range
$73.89 – $74.90
52W range
$59.70 – $89.77
Mkt cap
$34.07B
P/E
16.2
EPS
$4.55
Beta
1.30
  • Yahoo·9h ago

    Stryker to Acquire AVS, Adding IVL Capabilities to Vascular Portfolio

    SYK to acquire Amplitude Vascular Systems, adding next-gen IVL tech to boost its peripheral vascular portfolio and expand arterial disease treatment reach.

  • Yahoo·10h ago

    Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

    ECL stock gains on strong Q4 results and expanding high-tech water solutions and digital platforms. Ovivo deal and R&D push support growth amid macro headwinds.

  • Yahoo·10h ago

    Avantor Stock Up as New Lab Capabilities Improve Biopharma Support

    AVTR stock gains after expanding U.S. lab capabilities, boosting biopharma support, streamlining testing and strengthening supply chain efficiency.

  • Yahoo·13h ago

    3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

    Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

  • Yahoo·1d ago

    RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data

    Revvity launches Signals BioDesign, a cloud-based cloning platform to streamline biotech R&D workflows and boost collaboration in biologics development.

  • Benzinga·1d ago

    Mizuho Maintains Outperform on GE HealthCare Techs, Lowers Price Target to $90

    Mizuho analyst Anthony Petrone maintains GE HealthCare Techs (NASDAQ:GEHC) with a Outperform and lowers the price target from $95 to $90.

  • SeekingAlpha·1d ago

    GE HealthCare: A Better Proposition Here

  • Yahoo·3d ago

    GE HealthCare Ultrasound Link With Medtronic Adds New Neurosurgery Angle

    GE HealthCare Technologies (NasdaqGS:GEHC) has launched a digital integration between its bkActiv ultrasound system and Medtronic's Stealth AXiS surgical navigation platform. The combined solution is now commercially available for neurosurgical procedures, offering real time imaging support in cranial surgery. The integration is designed to address brain shift during operations, a key challenge that can affect surgical accuracy. For investors watching GE HealthCare at a share price of...

  • View all news →

Fundamentals

Valuation
Market Cap
$34.07B
P/E (TTM)
16.16S&P avg ~22
P/S (TTM)
1.63S&P avg ~2.8
P/B
3.60S&P avg ~4.5
P/FCF
22.38S&P avg ~26
EPS (TTM)
$4.55
Book/sh
$22.77
Cash/sh
$9.86
Profitability
Gross Margin
39.98%avg ~45%
Operating Margin
13.40%avg ~15%
Net Margin
10.11%avg ~12%
ROE
21.24%avg ~18%
ROA
5.87%avg ~7%
ROI
10.59%
Payout Ratio
3.07%
FCF/sh
—
Growth & Health
Rev Growth YoY
4.85%
Rev Growth 5Y
3.74%
EPS Growth YoY
4.78%
EPS Growth 5Y
-31.63%
Current Ratio
—
Quick Ratio
1.10
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.30
52W High
$89.77
52W Low
$59.70
Avg Vol (10D)
3.21M
Avg Vol (3M)
3.43M
Div Yield
0.19%
Div/sh (TTM)
—
Analyst
Buy (28)
Price Performance
5D+5.88%
MTD+3.72%
3M-16.25%
6M-3.38%
YTD-9.99%
1Y+18.55%

Factor Grades

View details →
C+
Overall score: 56/100
B+
Valuation
D+
Growth
C+
Profitability
D+
Momentum
B
Financial Health
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B2 on 2025-12-02. View all →

Recent insider activity

View all →
  • 4FORM 4
    29d ago
  • 4FORM 4
    Mar 4
  • 4FORM 4
    Mar 4
  • 4FORM 4
    Mar 4
  • 4FORM 4
    Mar 4